FutureTech II Acquisition (FTII) S-414 Feb 25Registration of securities issued in business combination transactionsFinancial data

Company Profile

Cover

Cover	9 Months Ended
Cover	Sep. 30, 2024
Entity Addresses [Line Items]
Document Type	S-4
Amendment Flag	false
Entity Registrant Name	FutureTech II Acquisition Corp.
Entity Central Index Key	0001889450
Entity Tax Identification Number	87-2551539
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	128 Gail Drive
Entity Address, City or Town	New Rochelle
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10805
City Area Code	646
Local Phone Number	978-5180
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	FutureTech II Acquisition Corp.
Entity Address, Address Line Two	128 Gail Drive
Entity Address, City or Town	New Rochelle
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10805
City Area Code	(914
Local Phone Number	316-4805
Contact Personnel Name	Ray Chen

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash	$ 1,883	$ 17,578	$ 262,756
Prepaid expenses	20,250	64,043	157,614
Extension fee receivable		125,000
Due from Sponsor	1,540,984	1,179,141
Total Current Assets	1,563,117	1,385,762	420,370
Marketable Securities held in Trust Account	26,932,536	61,839,164	118,976,585
Prepaid expenses, non-current			77,654
Total Assets	28,495,653	63,224,926	119,474,609
Current Liabilities:
Accounts payable and accrued expenses	611,188	295,137	130,225
Excise tax payable	1,005,209	642,389
Franchise tax payable	78,914	94,364	200,000
Income tax payable	1,053,426	1,087,603	310,259
Accrued offering costs	2,708	2,708	2,708
Note payable - Sponsor	3,450,000	2,925,000	144,443
Total Current Liabilities	6,201,445	5,047,201	787,635
Deferred underwriting commission	3,450,000	3,450,000	3,450,000
Total Liabilities	9,651,445	8,497,201	4,237,635
COMMITMENTS AND CONTINGENCIES (Note 7)
Stockholders’ deficit:
Preferred shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding
Additional paid-in capital
Accumulated deficit	(7,762,739)	(6,499,430)	(3,229,704)
Total Stockholders’ Deficit	(7,762,387)	(6,499,078)	(3,229,352)
Total Liabilities and Stockholders’ Deficit	28,495,653	63,224,926	119,474,609
Common Class A [Member]
Current Liabilities:
Class A common stock, $0.0001 par value; 100,000,000 shares authorized; 5,556,350 and 11,500,000 shares subject to possible redemption issued and outstanding shares at redemption value of $11.02 and $10.30 per share as of December 31, 2023 and December 31, 2022, respectively	26,606,595	61,226,803	118,466,326
Stockholders’ deficit:
Common stock, value	64	64	64
Common Class B [Member]
Stockholders’ deficit:
Common stock, value	$ 288	$ 288	$ 288

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Preferred stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000	1,000,000
Preferred stock, shares issued	0	0	0
Preferred stock, shares outstanding	0	0	0
Common Class A [Member]
Temporary equity, par value	$ 0.0001	$ 0.0001	$ 0.0001
Temporary equity, shares authorized	100,000,000	100,000,000	100,000,000
Temporary equity, shares issued	2,319,435	5,556,350	11,500,000
Temporary equity, shares oustanding	2,319,435	5,556,350	11,500,000
Temporary equity, redemption per share	$ 11.47	$ 11.02	$ 10.30
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000	100,000,000
Common stock, shares issued	635,075	635,075	635,075
Common stock, shares outstanding	635,075	635,075	635,075
Common stock representative shares	115,000	115,000	115,000
Common stock, shares subject to possible redemption		5,556,350	11,500,000
Common Class B [Member]
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	10,000,000	10,000,000	10,000,000
Common stock, shares issued	2,875,000	2,875,000	2,875,000
Common stock, shares outstanding	2,875,000	2,875,000	2,875,000

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
Condensed Statements of Operations - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
EXPENSES
Administrative fee - related party					$ 120,000	$ 100,000
Franchise tax	$ 50,000	$ 50,000	$ 150,000	$ 150,000	200,000	200,000
General and administrative	287,118	249,254	722,945	650,820	742,699	366,311
TOTAL EXPENSES	367,118	329,254	962,945	890,820	1,062,699	666,311
OTHER INCOME
Interest earned on marketable securities held in Trust Account	287,584	1,232,507	1,107,012	3,989,390	4,809,102	1,676,585
Gain on forgiveness of debt					144,443
TOTAL OTHER INCOME	287,584	1,232,507	1,107,012	3,989,390	4,953,545	1,676,585
Pre-tax income (loss)	(79,534)	903,253	144,067	3,098,570	3,890,846	1,010,274
Income tax	(43,593)	(242,027)	(182,072)	(793,671)	(979,344)	(310,259)
Net income (loss)	(123,127)	661,226	(38,005)	2,304,899	2,911,502	700,015
Redeemable [Member]
OTHER INCOME
Net income (loss)	$ (163,413)	$ (406,478)	$ (513,195)	$ (1,263,723)	$ (2,982,080)	$ (1,323,201)
Weighted average number of shares of non-redeemable common stock outstanding, basic	2,319,435	8,657,385	2,851,045	10,542,049	9,285,380	11,500,000
Weighted average number of shares of non-redeemable common stock outstanding, diluted	2,319,435	8,657,385	2,851,045	10,542,049	9,285,380	11,500,000
Basic net income (loss) per share of non-redeemable common stock	$ (0.23)	$ 0.10	$ (0.02)	$ 0.26	$ 0.21	$ 0.03
Diluted net income (loss) per share of non-redeemable common stock	$ (0.23)	$ 0.10	$ (0.02)	$ 0.26	$ 0.21	$ 0.03
Non Redeemable [Member]
OTHER INCOME
Net income (loss)	$ (247,298)	$ (164,803)	$ (631,822)	$ (420,768)	$ (560,177)	$ (228,369)
Weighted average number of shares of non-redeemable common stock outstanding, basic	3,510,075	3,510,075	3,510,075	3,510,075	3,510,075	3,510,075
Weighted average number of shares of non-redeemable common stock outstanding, diluted	3,510,075	3,510,075	3,510,075	3,510,075	3,510,075	3,510,075
Basic net income (loss) per share of non-redeemable common stock	$ (0.07)	$ (0.05)	$ (0.18)	$ (0.12)	$ (0.16)	$ (0.07)
Diluted net income (loss) per share of non-redeemable common stock	$ (0.07)	$ (0.05)	$ (0.18)	$ (0.12)	$ (0.16)	$ (0.07)
Related Party [Member]
EXPENSES
Administrative fee - related party	$ 30,000	$ 30,000	$ 90,000	$ 90,000	$ 120,000	$ 100,000

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders' Deficit - USD ($)	Common Stock [Member] Common Class A [Member]	Common Stock [Member] Common Class B [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021		$ 288	$ 24,712	$ (438)	$ 24,562
Balance, shares at Dec. 31, 2021		2,875,000
Remeasurement adjustment			2,762,954	(3,929,281)	(1,166,327)
Net income (loss)				700,015	700,015
Excise tax payable			3,450,000		3,450,000
Sale of units in Initial Public Offering	$ 1,150		115,000,000		115,000,000
Sale of units in Initial Public Offering, net of offering costs, shares	11,500,000
Offering costs			(2,239,502)		(2,239,502)
Sale of Private Placement Units	$ 52		5,200,968		5,200,750
Sale of Private Placement Units, shares	520,075
Shares issued to representative	$ 12		(12)
Shares issued to representative, shares	115,000
Deferred underwriting commission			(3,450,000)		(3,450,000)
Class A Common Stock subject to possible redemption	$ (1,150)		(117,298,850)		(117,300,000)
Class A Common Stock subject to possible redemption, shares	(11,500,000)
Balance at Dec. 31, 2022	$ 64	$ 288		(3,229,704)	(3,229,352)
Balance, shares at Dec. 31, 2022	635,075	2,875,000
Remeasurement adjustment				(2,128,414)	(2,128,414)
Net income (loss)				807,289	807,289
Balance at Mar. 31, 2023	$ 64	$ 288		(4,550,829)	(4,550,477)
Balance, shares at Mar. 31, 2023	635,075	2,875,000
Balance at Dec. 31, 2022	$ 64	$ 288		(3,229,704)	(3,229,352)
Balance, shares at Dec. 31, 2022	635,075	2,875,000
Net income (loss)					2,304,899
Balance at Sep. 30, 2023	$ 64	$ 288		(6,261,793)	(6,261,441)
Balance, shares at Sep. 30, 2023	635,075	2,875,000
Balance at Dec. 31, 2022	$ 64	$ 288		(3,229,704)	(3,229,352)
Balance, shares at Dec. 31, 2022	635,075	2,875,000
Net income (loss)				2,911,502	2,911,502
Capital contribution				1,013,297	1,013,297
Accretion to redemption value				(6,552,136)	(6,552,136)
Excise tax on Class A common stock redemption				(642,389)	(642,389)
Balance at Dec. 31, 2023	$ 64	$ 288		(6,499,430)	(6,499,078)
Balance, shares at Dec. 31, 2023	635,075	2,875,000
Balance at Mar. 31, 2023	$ 64	$ 288		(4,550,829)	(4,550,477)
Balance, shares at Mar. 31, 2023	635,075	2,875,000
Remeasurement adjustment				(1,126,824)	(1,126,824)
Net income (loss)				836,383	836,383
Balance at Jun. 30, 2023	$ 64	$ 288		(4,841,270)	(4,840,918)
Balance, shares at Jun. 30, 2023	635,075	2,875,000
Remeasurement adjustment				(2,090,482)	(2,090,482)
Net income (loss)				661,226	661,226
Capital contribution				8,733	8,733
Balance at Sep. 30, 2023	$ 64	$ 288		(6,261,793)	(6,261,441)
Balance, shares at Sep. 30, 2023	635,075	2,875,000
Balance at Dec. 31, 2023	$ 64	$ 288		(6,499,430)	(6,499,078)
Balance, shares at Dec. 31, 2023	635,075	2,875,000
Net income (loss)				129,577	129,577
Capital contribution				48,666	48,666
Excise tax payable				(362,820)	(362,820)
Accretion to redemption value				(615,511)	(615,511)
Deferred underwriting commission				362,820	362,820
Balance at Mar. 31, 2024	$ 64	$ 288		(7,299,518)	(7,299,166)
Balance, shares at Mar. 31, 2024	635,075	2,875,000
Balance at Dec. 31, 2023	$ 64	$ 288		(6,499,430)	(6,499,078)
Balance, shares at Dec. 31, 2023	635,075	2,875,000
Net income (loss)					(38,005)
Balance at Sep. 30, 2024	$ 64	$ 288		(7,762,739)	(7,762,387)
Balance, shares at Sep. 30, 2024	635,075	2,875,000
Balance at Mar. 31, 2024	$ 64	$ 288		(7,299,518)	(7,299,166)
Balance, shares at Mar. 31, 2024	635,075	2,875,000
Net income (loss)				(44,457)	(44,457)
Capital contribution				309,391	309,391
Accretion to redemption value				(340,436)	(340,436)
Balance at Jun. 30, 2024	$ 64	$ 288		(7,375,020)	(7,374,668)
Balance, shares at Jun. 30, 2024	635,075	2,875,000
Net income (loss)				(123,127)	(123,127)
Capital contribution				79,399	79,399
Accretion to redemption value				(343,992)	(343,992)
Balance at Sep. 30, 2024	$ 64	$ 288		$ (7,762,739)	$ (7,762,387)
Balance, shares at Sep. 30, 2024	635,075	2,875,000

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($)	9 Months Ended		12 Months Ended
Condensed Statements of Cash Flows - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Cash flows from Operating Activities:
Net income	$ (38,005)	$ 2,304,899	$ 2,911,502	$ 700,015
Adjustments to reconcile net income to net cash used in operating activities:
Income earned on marketable securities held in the Trust Account	(1,107,012)	(3,989,390)	(4,809,102)	(1,676,585)
Gain on forgiveness of debt			(144,443)
Changes in operating assets and liabilities:
Prepaid expenses	43,793	26,209	93,571	(157,614)
Due from Sponsor			(731,912)
Franchise tax payable	(15,450)	(155,636)	(105,636)	200,000
Income tax payable	(34,177)	591,672	777,344	310,259
Other assets		77,654	77,654	(77,654)
Accounts payable and accrued expenses	316,048	178,313	164,913	100,225
Net cash used in operating activities	(834,803)	(966,279)	(1,766,109)	(601,354)
Cash flows from Investing Activities:
Investment of cash in Trust Account	(650,000)	(2,550,000)	(2,800,000)	(117,300,000)
Cash in transit to the trust	125,000		(125,000)
Cash withdrawn from Trust	36,663,640	64,746,521	64,746,521
Net cash provided by (used in) investing activities	36,138,640	62,196,521	61,821,521	(117,300,000)
Cash flows from Financing Activities:
Proceeds from sale of Units, net of underwriting discount paid				115,000,000
Proceeds from sale of private placement units				5,200,750
Underwriting fee paid				(1,725,000)
Note receivable				(100,000)
Note receivable - repayment				100,000
Payment of deferred offering costs				(316,640)
Proceeds from Sponsor note	525,000	3,316,485	2,925,000
Capital contribution from Sponsor	437,458		1,013,297
Cash paid for redemptions	(36,281,990)	(64,238,887)	(64,238,887)
Advance to Sponsor		(565,100)
Net cash (used in) provided by financing activities	(35,319,532)	(61,487,502)	(60,300,590)	118,159,111
Net change in cash	(15,695)	(257,260)	(245,178)	257,756
Cash - Beginning of the period	17,578	262,756	262,756	5,000
Cash - End of the period	1,883	5,496	17,578	262,756
Supplemental disclosure of non-cash financing activities:
Accretion to redemption value	1,299,939	5,345,720	6,552,136	3,929,281
Excise tax on Class A common stock redemptions	362,820		642,389
Capital contribution from Sponsor		8,733
Due from Sponsor		447,229
Overpayment of redemption amount included in Due from Sponsor	$ 361,843
Deferred underwriting commission				3,450,000
Initial Classification of Class A common stock subject to redemption				118,553,638
Offering costs paid by Promissory note - related parties				$ 187,993

Description of Organization and

Description of Organization and Business Operations, Going Concern and Basis of Presentation	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Description of Organization and Business Operations, Going Concern and Basis of Presentation	Note 1 - Description of Organization and Business Operations, Going Concern and Basis of Presentation FutureTech II Acquisition Corp. (the “Company”) is a blank check company incorporated in Delaware on August 19, 2021. The Company was formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses (the “Business Combination”). The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of September 30, 2024, the Company had not commenced any operations. All activity for the period from April 13, 2021 (inception) through September 30, 2024 relates to organizational activities, identifying a target company for a business combination, and activities in connection with the proposed Business Combination with Longevity The registration statement for the Initial Public Offering was declared effective on February 14, 2022. On February 18, 2022, the Company consummated the Initial Public Offering of 11,500,000 115,000,000 Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 520,075 10.00 5,200,750 Following the closing of the Initial Public Offering on February 18, 2022, an amount of $ 117,300,000 10.00 3.72 Transaction costs of the Initial Public Offering with the exercise of the overallotment option amounted to $ 5,688,352 1,725,000 3,450,000 513,352 Following the closing of the Initial Public Offering, $ 700,000 1,883 4,638,328 17,578 3,661,439 Note 1 – Description of Organization and Business Operations. Going Concern and Basis of Presentation (Continued) The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. NASDAQ rules provide that the Business Combination must be with one or more target businesses that together have a fair market value equal to at least 80 50 The Company has until August 18, 2025 to consummate a Business Combination (the “Combination Period”). If the Company is unable to complete a Business Combination by the end of the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes (less any applicable taxes and permitted expenses and up to $ 100,000 The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or similar agreement or Business Combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $ 10.20 10.20 Note 1 – Description of Organization and Business Operations, Going Concern and Basis of Presentation (Continued) Business Combination On September 16, 2024, the Company, entered into an Agreement and Plan of Merger (the “Merger Agreement”), with Longevity Biomedical, Inc., a Delaware corporation (“Longevity”), LBI Merger Sub, Inc., a Delaware corporation and direct, wholly-owned subsidiary of the Company (“Merger Sub”), and Bradford A. Zakes, solely in the capacity as seller representative. The Merger Agreement provides that the parties thereto will enter into a business combination transaction (the “Longevity Business Combination” and together with the other transactions contemplated by the Merger Agreement, the “Transactions”), pursuant to which, among other things, (i) Longevity will consummate Target Acquisitions (as defined therein) upon the terms and subject to conditions set forth therein and pursuant to the Target Acquisition Agreements (as defined therein), and (ii) immediately following the consummation of the Target Acquisitions, Longevity will merge with and into Merger Sub (the “Merger”) with Longevity as the surviving company of the Merger. Following the Merger, Longevity will be a wholly-owned subsidiary of the Company. At the closing of the Transactions (the “Closing”), the Company is expected to change its name to “Longevity Biomedical, Inc.” and the Company’s common stock is expected to list on the NASDAQ Stock Market under the ticker symbol “LBIO.” The consummation of the proposed Longevity Business Combination is subject to certain conditions as further described in the Merger Agreement. In connection with the execution of the Merger Agreement, the sole stockholder of Longevity (the “Voting Stockholder”) has entered into a Voting and Support Agreement (the “Longevity Support Agreement”), pursuant to which the Voting Stockholder has agreed to, among other things, (i) vote in favor of the Merger Agreement and the transactions contemplated thereby and (ii) be bound by certain other covenants and agreements related to the Transactions. The Voting Stockholder holds sufficient shares of Longevity to cause the approval of the Transactions on behalf of Longevity. In connection with the execution of the Merger Agreement, the Company, Longevity and the Sponsor have entered into a Voting and Support Agreement (the “Sponsor Support Agreement”). The Sponsor Support Agreement provides that the Sponsor agrees (i) to vote in favor of the proposed transactions contemplated by the Merger Agreement, (ii) to appear at the purchaser special meeting for purposes of constituting a quorum, (iii) to vote against any proposals that would materially impede the proposed transactions contemplated by the Merger Agreement, (iv) to not redeem any shares of the Company’s Common Stock held by it that may be redeemed, and (v) to waive any adjustment to the conversion ratio set forth in the Company’s amended and restated certificate of incorporation (as amended from time to time, the “Charter”) with respect to shares of the Class B Common Stock of the Company held by the Sponsor, in each case, on the terms and subject to the conditions set forth in the Sponsor Support Agreement. On September 20, 2024, the Company filed a Form 8-K with the SEC to report the Merger Agreement and other legal agreements relating to the Longevity Business Combination. Liquidity and Management’s Plans At September 30, 2024, the Company had cash of $ 1,883 4,638,328 At December 31, 2023, the Company had cash of $ 17,578 3,661,439 Based on the foregoing, unless the Company can raise additional capital, including continuing funding from the Sponsor, the management believes that the Company will not have sufficient working capital and borrowing capacity to meet its needs through the consummation of the Business Combination. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. In accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” the Company has evaluated that there are certain conditions and events, considered in the aggregate, that raise doubt about the Company’s ability to continue as a going concern through until August 18, 2025 , the date that the Company is required to cease all operations, except for the purpose of winding up, if a Business Combination is not consummated by such date. It is uncertain that the Company will be able to consummate an initial Business Combination by this time. If an initial Business Combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution of the Company. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The unaudited condensed financial statements do not include any adjustments that might result from the Company’s inability to continue as a going concern. Risks and Uncertainties Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that while it is possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of the unaudited condensed financial statements. The unaudited condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty. In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Separately, in October 2023, Israel and certain Iranian-backed Palestinian forces began an armed conflict in Israel, the Gaza Strip, and surrounding areas, which threatens to spread to other Middle Eastern countries including Lebanon and Iran. The impact of these conflicts and related sanctions on the world economy are not determinable as of the date of these unaudited condensed financial statements. The specific impact on the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of these unaudited condensed financial statements. Note 1 – Description of Organization and Business Operations, Going Concern and Basis of Presentation (Continued) On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1 1 Additionally, shares of our Class A Common Stock and public warrants are listed on Nasdaq. Nasdaq IM-5101-2 requires that the Company, a special purpose acquisition company, complete one or more business combinations within 36 months of the effectiveness of its initial public offering registration statement, which, in the case of the Company, would be February 14, 2025. If the Company is unable to complete an initial business combination by February 14, 2025 and seeks to extend beyond such 36-month period, such extension would violate Nasdaq IM-5101-2. Effective on October 7, 2024, Nasdaq Rule 5815 was amended to provide for the immediate suspension and delisting upon issuance of a delisting determination letter to an issuer for failure to meet the requirements of Nasdaq IM5101-02. Accordingly, the Company will face immediate suspension and delisting of its securities once the Company receives a delisting determination letter from Nasdaq after the 36-month window ends on February 14, 2025. Pursuant to Nasdaq Rule 5815, as amended, Nasdaq may only reverse its delisting determination if it finds that it made a factual error in applying Nasdaq Rule 5815, as amended. If Nasdaq delists the Company’s securities from trading on its exchange and the Company is not able to list its securities on another national securities exchange, we expect the Company’s securities could be quoted on an over-the-counter market. If this were to occur, we could face significant material adverse consequences, including our ability to consummate the Business Combination; reduced liquidity for our securities; a limited availability of market quotations for our securities; a determination that our shares of common stock are a “penny stock” which will require brokers trading in our shares of common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; a decreased ability to issue additional securities or obtain additional financing in the future; a limited amount of news and analyst coverage; and becoming a less attractive merger partner for a target company or business. We also note that if Nasdaq delists the Company’s securities from trading on its exchange and the Company is not able to list its securities on another national securities exchange, it may affect the Company’s ability to consummate its planned Business Combination with Longevity. In addition, the Company’s ability to consummate a transaction may be dependent on the ability to raise equity or debt financing which may be impacted by these events, including as a result of increased market volatility, or decreased market liquidity in third-party financing being unavailable on terms acceptable to the Company or at all. The impact of this action and related sanctions on the world economy and the specific impact on the Company’s financial position, results of operations and/or ability to consummate a Business Combination are not yet determinable. The unaudited condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.	Note 1 - Description of Organization and Business Operations, Going Concern and Basis of Presentation FutureTech II Acquisition Corp. (the “Company”) is a blank check company incorporated in Delaware on August 19, 2021. The Company was formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses (the “Business Combination”). The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of December 31, 2023, the Company had not commenced any operations. All activity for the period from April 13, 2021 (inception) through December 31, 2023 relates to organizational activities and identifying a target company for a business combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the Company’s initial public offering (the “Initial Public Offering”). The Company has selected December 31 as its fiscal year end. The registration statement for the Initial Public Offering was declared effective on February 14, 2022. On February 18, 2022, the Company consummated the Initial Public Offering of 11,500,000 115,000,000 Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 520,075 10.00 5,200,750 Following the closing of the Initial Public Offering on February 18, 2022, an amount of $ 117,300,000 10.00 Transaction costs of the Initial Public Offering with the exercise of the overallotment amounted to $ 5,688,352 1,725,000 3,450,000 513,352 Following the closing of the Initial Public Offering, $ 700,000 17,578 3,661,439 262,756 367,265 The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. NASDAQ rules provide that the Business Combination must be with one or more target businesses that together have a fair market value equal to at least 80% of the balance in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on interest earned on the Trust Account) at the time of the signing of a definitive agreement to enter a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50 The Company has until April 18, 2024 (or up to November 18, 2024, if extended) to consummate a Business Combination (the “Combination Period”). If the Company is unable to complete a Business Combination by the end of the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes (less up to $ 100,000 The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or similar agreement or Business Combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $ 10.20 10.20 FUTURETECH II ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS Note 1 - Description of Organization and Business Operations, Going Concern and Basis of Presentation (Continued) Use of Funds Restricted for Payment of Taxes In 2024, in connection with redemptions that occurred in August 2023, the Company determined it did not withdraw all the interest from the trust account that it was allowed to withdraw to cover federal income and State of Delaware franchise taxes which had accrued and, therefore, the redemption payment should have been adjusted down to approximately $ 10.74 447,229 447,229 Liquidity and Management’s Plans At December 31, 2023, the Company had cash of $ 17,578 3,661,439 At December 31, 2022, the Company had cash of $ 262,756 367,265 In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” the Company has until April 18, 2024 (or up to November 18, 2024, if extended) to complete a Business Combination. It is uncertain that the Company will be able to consummate an initial Business Combination by this time. If an initial Business Combination is not consummated by this date and the Company has not exercised its option to extend the deadline, there will be a mandatory liquidation and subsequent dissolution of the Company. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the Company’s inability to continue as a going concern. Risks and Uncertainties Management is currently evaluating the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of the financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Additionally, as a result of the military action that commenced in February 2022 by the Russian Federation and Belarus in the country of Ukraine and related economic sanctions, the Company’s ability to consummate a Business Combination or the operations of a target business with which the Company ultimately consummates a Business Combination may be materially and adversely affected. Further, the Company’s ability to consummate a transaction may be dependent on the ability to raise equity and debt financing which may be impacted by these events, including as a result of increased market volatility, or decreased market liquidity in third-party financing being unavailable on terms acceptable to the Company or at all. The impact of this action and related sanctions on the world economy and the specific impact on the Company’s financial position, results of operations and/or ability to consummate a Business Combination are not yet determinable. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 - Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC). Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of the Company’s management, the unaudited condensed financial statements as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023 include all adjustments, which are only of a normal and recurring nature, necessary for a fair statement of the financial position of the Company as of September 30, 2024 and its results of operations and cash flows for the three and nine months ended September 30, 2024 and 2023. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2024 or any future interim period. Note 2 - Summary of Significant Accounting Policies (Continued) Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company, which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of unaudited condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Concentration of Credit Risk Financial instruments that potentially subject to concentration of credit risk consist of cash and cash held in trust. Cash is comprised of cash balances with banks and bank deposits, which are insured by the Federal Deposit Insurance Company (“FDIC”), up to $ 250,000 no 250,000 250,000 26,682,536 61,589,164 Derivative The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC 815. “Derivatives and Hedging”. Derivative instruments are initially recorded at fair value on the grant date and re-valued at each reporting date, with changes in the fair value reported in the unaudited condensed statements of operations. Derivative assets and liabilities are classified in the unaudited condensed balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Company accounts for the warrants in accordance with the guidance contained in ASC 815-40. The Company has determined that the warrants qualify for equity treatment in the Company’s unaudited condensed financial statements. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value. As of September 30, 2024 and December 31, 2023, the Company had cash of $ 1,883 17,578 no Trust Account Upon the closing of the Initial Public Offering and the Private Placement, $ 117,300,000 10.00 Note 2- Summary of Significant Accounting Policies (Continued) As of September 30, 2024 and December 31, 2023, the Company had $ 26,932,536 61,839,164 Offering Costs Associated with the Initial Public Offering The Company complies with the requirements of the Financial Accounting Standards Board ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“ SAB Expenses of Offering 513,352 1,725,000 Class A Common Stock Subject to Possible Redemption The Company accounts for its common stock subject to possible redemption in accordance with the guidance enumerated in ASC 480 “ Distinguishing Liabilities from Equity 26,606,595 61,226,803 34,620,208 36,281,990 1,299,939 361,843 As of September 30, 2024 and December 31, 2023, the shares of common stock reflected on the unaudited condensed balance sheets are reconciled in the following table. Schedule of Common Stock Reflected on Balance Sheet Reconciled Ending Balance as of December 31, 2022 $ 118,466,326 Redemption of Class A common stock (64,238,888 ) Remeasurement of carrying value to redemption value 6,552,136 Due from Sponsor 447,229 Ending Balance as of December 31, 2023 61,226,803 Redemption of Class A common stock (36,281,990 ) Remeasurement of carrying value to redemption value 615,511 Due from Sponsor 361,843 Ending Balance as of March 31, 2024 25,922,167 Remeasurement of carrying value to redemption value 340,437 Ending Balance as of June 30, 2024 26,262,604 Remeasurement of carrying value to redemption value 343,991 Ending Balance as of September 30, 2024 $ 26,606,595 Warrant Instruments The Company accounts for the Public Warrants and the Private Placement Warrants issued in connection with the Initial Public Offering and the Private Placement in accordance with the guidance contained in FASB ASC 815, “Derivatives and Hedging”. Under ASC 815-40 the Public Warrants and the Private Placement Warrants meet the criteria for equity treatment and as such will be recorded in stockholders’ deficit. If the warrants no longer meet the criteria for equity treatment, they will be recorded as a liability and remeasured each period with changes recorded in the unaudited condensed statement of operations. Net Income (Loss) Per Share Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. The Company applies the two-class method in calculating earnings per share. Earnings and losses are shared pro rata between the two classes of shares. The calculation of diluted income (loss) per share of common stock does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering and (ii) sale of the Private Placement Units, because the warrants are contingently exercisable, and the contingencies have not yet been met. As a result, diluted income (loss)per share is the same as basic income (loss) per share for the periods presented. Note 2 - Summary of Significant Accounting Policies (Continued) The following table reflects the calculation of basic and diluted net income (loss) per share (in dollars, except per share amounts): Schedule of Basic and Diluted Net Income (Loss) Per Common Share Three Months Ended Three Months Ended September 30, 2024 September 30, 2023 Redeemable Non-redeemable Redeemable Non-redeemable Basic and diluted net income (loss) per share of common stock Numerator: Interest $ 287,584 $ - $ 1,232,507 $ - Less: Allocation of expenses (163,413 ) (247,298 ) (406,478 ) (164,803 ) Less: Accretion of carrying value to redemption value (649,442 ) - - - Total $ (525,271 ) $ (247,298 ) $ 826,029 $ (164,803 ) Basic and diluted net income (loss) per share of common stock $ (0.23 ) $ (0.07 ) $ 0.10 $ (0.05 ) Nine Months Ended Nine Months Ended September 30, 2024 September 30, 2023 Redeemable Non-redeemable Redeemable Non-redeemable Basic and diluted net income (loss) per share of common stock Numerator: Interest $ 1,107,012 $ - $ 3,989,390 $ - Less: Allocation of expenses (513,195 ) (631,822 ) (1,263,723 ) (420,768 ) Less: Accretion of carrying value to redemption value (649,442 ) - - - Total $ (55,625 ) $ (631,822 ) $ 2,725,667 $ (420,768 ) Basic and diluted net income (loss) per share of common stock $ (0.02 ) $ (0.18 ) $ 0.26 $ (0.12 ) Fair Value of Financial Instruments The fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets. This is the level that the Interest Bearing Bank Demand Deposit Account Held in Trust Account are considered (being $ 26,932,536 61,839,164 ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. Note 2 - Summary of Significant Accounting Policies (Continued) Income Taxes The Company complies with the accounting and reporting requirements of ASC Topic 740, “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined the United States is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were no no In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires disaggregated information about a reporting entity’s effective tax rate reconciliation, as well as information related to income taxes paid to enhance the transparency and decision usefulness of income tax disclosures. This ASU will be effective for the annual period ending December 31, 2025. The Company is currently assessing what impact, if any, that ASU 2023-09 would have on its financial position, results of operations or cash flows. New Law and Changes On August 16, 2022, the Inflation Reduction Act (the “IR Act”) was signed into law, which, beginning in 2023, will impose a 1 The IR Act imposes a 1 Nasdaq IM-5101-2 requires that the Company, a special purpose acquisition company, complete one or more business combinations within 36 months of the effectiveness of its initial public offering registration statement, which, in the case of the Company, would be February 14, 2025. If the Company is unable to complete an initial business combination by February 14, 2025 and seeks to extend beyond such 36-month period, such extension would violate Nasdaq IM-5101-2. Effective on October 7, 2024, Nasdaq Rule 5815 was amended to provide for the immediate suspension and delisting upon issuance of a delisting determination letter to an issuer for failure to meet the requirements of Nasdaq IM5101-02. Accordingly, the Company will face immediate suspension and delisting of its securities once the Company receives a delisting determination letter from Nasdaq after the 36-month window ends on February 14, 2025. Pursuant to Nasdaq Rule 5815, as amended, Nasdaq may only reverse its delisting determination if it finds that it made a factual error in applying Nasdaq Rule 5815, as amended. Recently Issued Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited condensed financial statements.	Note 3 - Summary of Significant Accounting Policies Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company, which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal depository insurance coverage of $ 250,000 FUTURETECH II ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS Note 3 - Summary of Significant Accounting Policies (Continued) Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value. As of December 31, 2023 and 2022, the Company had cash of $ 17,578 262,756 Trust Account Upon the closing of the Initial Public Offering and the Private Placement, $ 117,300,000 10.00 As of December 31, 2023 and 2022, the Company had $ 61,839,164 118,976,585 Offering Costs Associated with the Initial Public Offering The Company complies with the requirements of the Financial Accounting Standards Board ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“ SAB Expenses of Offering 513,352 1,725,000 Class A Common Stock Subject to Possible Redemption The Company accounts for its common stock subject to possible redemption in accordance with the guidance enumerated in ASC 480 “ Distinguishing Liabilities from Equity 61,226,803 118,466,326 57,239,523 64,238,888 6,552,136 447,229 As of December 31, 2023 (restated) and 2022, the shares of common stock reflected on the balance sheet are reconciled in the following table. Schedule of Common Stock Reflected on Balance Sheet Reconciled Gross Proceeds $ 115,000,000 Less: Proceeds allocated to public warrants (1,067,463 ) Temporary equity offering costs (5,635,551 ) Plus: Remeasurement of carrying value to redemption value 9,003,014 Ending Balance as of March 31, 2022 117,300,000 Remeasurement of carrying value to redemption value 1,166,326 Ending Balance as of December 31, 2022 118,466,326 Redemption of Class A common stock (64,238,888 ) Remeasurement of carrying value to redemption value 6,552,136 Due from Sponsor 447,229 Ending Balance as of December 31, 2023 (restated) $ 61,226,803 Warrant Instruments The Company accounts for the Public Warrants and the Private Placement Warrants issued in connection with the Initial Public Offering and the Private Placement in accordance with the guidance contained in FASB ASC 815, “Derivatives and Hedging”. Under ASC 815-40 the Public Warrants and the Private Placement Warrants meet the criteria for equity treatment and as such will be recorded in stockholders’ deficit. If the warrants no longer meet the criteria for equity treatment, they will be recorded as a liability and remeasured each period with changes recorded in the statements of operations. Net Income (Loss) Per Share Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. The Company applies the two-class method in calculating earnings per share. Earnings and losses are shared pro rata between the two classes of shares. The calculation of diluted loss per share of common stock does not consider the effect of the warrants issued in connection with the (i) Initial Public Offering and (ii) sale of the Private Placement Units, because the warrants are contingently exercisable, and the contingencies have not yet been met. As a result, diluted income (loss) per share is the same as basic income (loss) per share for the periods presented. FUTURETECH II ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS Note 3 - Summary of Significant Accounting Policies (Continued) The following table reflects the calculation of basic and diluted net income (loss) per share (in dollars, except per share amounts): Schedule of Basic and Diluted Net Income (Loss) Per Common Share Year Ended Year Ended December 31, 2023 December 31, 2022 Redeemable Non-redeemable Redeemable Non-redeemable Basic and diluted net income (loss) per share of common stock Numerator: Interest $ 4,953,545 $ - $ 1,676,585 $ - Less: Allocation of net income (loss), as adjusted (2,982,080 ) (560,177 ) (1,323,201 ) (228,369 ) Total $ (1,971,465 ) $ (560,177 ) $ 353,384 $ (228,369 ) Basic and diluted net income (loss) per share of common stock $ 0.21 $ (0.16 ) $ 0.03 $ (0.07 ) Fair Value of Financial Instruments The fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets. This is the level that the Marketable Securities Held in Trust Account are considered (being $ 61,839,164 118,976,585 ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. Income Taxes The Company complies with the accounting and reporting requirements of ASC Topic 740, “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. FUTURETECH II ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS Note 3 - Summary of Significant Accounting Policies (Continued) ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined the United States is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense. There were no unrecognized tax benefits as of December 31, 2023 and 2022, no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires disaggregated information about a reporting entity’s effective tax rate reconciliation, as well as information related to income taxes paid to enhance the transparency and decision usefulness of income tax disclosures. This ASU will be effective for the annual period ending December 31, 2025. The Company is currently assessing what impact, if any, that ASU 2023-09 would have on its financial position, results of operations or cash flows. New Law and Changes On August 16, 2022, the Inflation Reduction Act (the “IR Act”) was signed into law, which, beginning in 2023, will impose a 1 The IR Act imposes a 1 Recently Issued Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements.

Public Offering

Public Offering	9 Months Ended	12 Months Ended
Public Offering	Sep. 30, 2024	Dec. 31, 2023
Public Offering
Public Offering	Note 3 - Public Offering Pursuant to the Initial Public Offering and full exercise of the underwriters’ overallotment option, the Company sold 11,500,000 10.00 11.50	Note 4 - Public Offering Pursuant to the Initial Public Offering and full exercise of the underwriters’ overallotment option, the Company sold 11,500,000 10.00 11.50

Private Placement

Private Placement	9 Months Ended	12 Months Ended
Private Placement	Sep. 30, 2024	Dec. 31, 2023
Private Placement
Private Placement	Note 4 - Private Placement Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 520,075 10.00 5,200,750 5,200,750 The proceeds from the sale of the Private Placement Units were added to the net proceeds from the Initial Public Offering held in the Trust Account. The warrants included in the Private Placement Units (the “Private Placement Warrants”) are identical to the warrants sold in the Initial Public Offering, except as described in Note 7. If the Company does not complete a Business Combination within the required period, the Private Placement Warrants will expire worthless.	Note 5 - Private Placement Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 520,075 10.00 5,200,750 5,200,750 The proceeds from the sale of the Private Placement Units were added to the net proceeds from the Initial Public Offering held in the Trust Account. The warrants included in the Private Placement Units (the “Private Placement Warrants”) are identical to the warrants sold in the Initial Public Offering, except as described in Note 8. If the Company does not complete a Business Combination within the required period, the Private Placement Warrants will expire worthless.

Related Party Transactions

Related Party Transactions	9 Months Ended	12 Months Ended
Related Party Transactions	Sep. 30, 2024	Dec. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 5 - Related Party Transactions Class B Common Stock On October 8, 2021, the Company issued an aggregate of 2,875,000 25,000 0.009 375,000 20 The initial stockholders have agreed not to transfer, assign or sell any of the Class B common stock (except to certain permitted transferees) until the earlier of (i) one year after the date of the consummation of a Business Combination, or (ii) the date on which the closing price of the Company’s common stock equals or exceeds $ 12.00 On November 18, 2024, the Company held a special stockholder meeting (the “Third Extension Meeting”) following the notice provided by the Definitive Proxy filed on Schedule 14A on October 31, 2024 (as amended and supplemented, the “Proxy Statement”) with the SEC, and stockholders approved by requisite votes to amend the Charter to provide for the right of the holders of Class B common stock, par value $ 0.0001 0.0001 Promissory Note - Related Party On August 19, 2021, the Sponsor issued an unsecured promissory note to the Company, pursuant to which the Company may borrow up to an aggregate principal amount of $ 300,000 The note is non-interest bearing and payable on the earlier of (i) March 31, 2022 or (ii) the consummation of the Initial Public Offering. As of September 30, 2024 and December 31, 2023, there is no amount outstanding pursuant to the promissory note, respectively. Related Party Loans In order to finance transaction costs in connection with a Business Combination, the Sponsor, an affiliate of the Sponsor, or the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (the “Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $ 1,500,000 10.00 Note 5 - Related Party Transactions ((Continued)) Extension Loan - Related Party On August 17, 2023, the Company held a special meeting of stockholders, at which the Company’s stockholders approved an amendment (the “First Charter Amendment”) to the Company’s Charter, and amendment to the Investment Management Trust Agreement, giving the Company the right to extend the deadline of Combination Period from August 18, 2023 to February 18, 2024, provided that the Sponsor (or its affiliates or permitted designees) will deposit into Trust Account the lesser of: (i) $ 125,000 0.04 On February 14, 2024, the Company held a special meeting of stockholders (the “Second Extension Meeting”), at which the Company’s stockholders approved an amendment (the “Second Charter Amendment”) to the Company’s Charter, giving the Company the right to extend the deadline of Combination Period from February 18, 2024 to November 18, 2024, provided that the Sponsor (or its affiliates or permitted designees) will deposit into Trust Account the lesser of: (i) $ 50,000 0.03 On November 18, 2024, the Company held the Third Extension Meeting (as defined above), at which the Company’s stockholders approved an amendment (the “Third Charter Amendment”) to the Company’s Charter, (i) giving the Company the right to extend the deadline of Combination Period from November 18, 2024 to August 18, 2025, provided that the Sponsor (or its affiliates or permitted designees) will deposit into Trust Account an aggregate amount equal to $ 0.05 Each deposit by the Sponsor for the First Charter Amendment, the Second Charter Amendment, the Third Charter Amendment and any additional future extension amendments are collectively referred to as the “Extension Loans”. On February 17, 2023 the Company caused to be deposited $ 1,150,000 0.10 1,150,000 0.10 125,000 125,000 125,000 125,000 125,000 On February 18, 2024, the Company caused to be deposited $ 50,000 50,000 50,000 50,000 50,000 50,000 50,000 50,000 50,000 On November 20, 2024, the Company caused to be deposited $ 37,744 37,744 37,744 As of September 30, 2024 and December 31, 2023, there was $ 3,300,000 2,925,000 As of January 27, 2025, there was approximately $ 3,400,000 Due from Sponsor As of September 30, 2024 and December 31, 2023 the Company had paid a total of $ 1,540,984 1,179,141 Administrative Support Agreement Commencing on the date the Units are first listed on Nasdaq, the Company has agreed to pay the Sponsor a total of $ 10,000 30,000 90,000 310,000 220,000 Representative Shares The Company issued to EF Hutton and/or its designees, 115,000 The representative shares have been deemed compensation by FINRA and are therefore subject to a lock-up for a period of 180 days immediately following the commencement of sales in the Initial Public Offering pursuant to Rule 5110(e)(1) of FINRA’s NASD Conduct Rules. Pursuant to FINRA Rule 5110(e)(1), these securities may not be sold, transferred, assigned, pledged or hypothecated or the subject of any hedging, short sale, derivative, put or call transaction that would result in the economic disposition of the securities by any person for a period of 180 days immediately following the effective date of the registration statement for the Initial Public Offering, nor may they be sold, transferred, assigned, pledged or hypothecated for a period of 180 days immediately following the commencement of sales in the Initial Public Offering except to any underwriter and selected dealer participating in the offering and their bona fide officers or partners, registered persons or affiliates or as otherwise permitted under Rule 5110(e)(2), and only if any such transferee agrees to the foregoing lock-up restrictions.	Note 6 - Related Party Transactions Class B Common Stock On October 8, 2021, the Company issued an aggregate of 2,875,000 25,000 0.009 375,000 20 FUTURETECH II ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS Note 6 - Related Party Transactions (Continued) The initial stockholders have agreed not to transfer, assign or sell any of the Class B common stock (except to certain permitted transferees) until the earlier of (i) one year after the date of the consummation of a Business Combination, or (ii) the date on which the closing price of the Company’s common stock equals or exceeds $ 12.00 Promissory Note - Related Party On August 19, 2021, the Sponsor issued an unsecured promissory note to the Company, pursuant to which the Company may borrow up to an aggregate principal amount of $ 300,000 The note is non-interest bearing and payable on the earlier of (i) March 31, 2022 or (ii) the consummation of the Initial Public Offering. 1,013,297 144,443 Related Party Loans In order to finance transaction costs in connection with a Business Combination, the Sponsor, an affiliate of the Sponsor, or the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (the “Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $ 1,500,000 10.00 Extension Loan - Related Party If the Company anticipates that it may not be able to consummate a Business Combination by the end of the Combination Period, the Company may, by resolution of the Company’s board if requested by the Sponsor, extend the period of time to consummate a Business Combination up to six times, each by an additional one month (for a total of up to 24 months to complete a Business Combination), subject to the Sponsor depositing additional funds into the Trust Account as set out below. Pursuant to the terms of the Company’s amended and restated certificate of incorporation, as amended (the “Charter”), and the trust agreement entered into between the Company and Continental Stock Transfer & Trust Company (as amended, the “Trust Agreement”), in order for the time available for the Company to consummate the initial Business Combination to be extended, the Sponsor or its affiliates or designees, upon five business days’ advance notice prior to the applicable deadline, must deposit into the Trust Account the lesser of: (i) $ 125,000 and (ii) an aggregate amount equal to $ 0.04 multiplied by the number of public shares of the Company that are not redeemed for each such one-month extension unless the closing of the Company’s initial business combination shall have occurred, in exchange for a non-interest bearing, unsecured promissory note payable upon consummation of a business combination (deposits made by the Sponsor in connection with the extension of the Combination Period, collectively, the “Extension Loans”). On February 17, 2023 the Company caused to be deposited $ 1,150,000 into the Company’s Trust Account for its public stockholders, representing $0.10 per public share, allowing the Company to extend the period of time it has to consummate its initial Business Combination by three months from February 18, 2023 to May 18, 2023. On May 17, 2023 the Company caused to be deposited $ 1,150,000 into the Company’s Trust Account for its public stockholders, representing $ 0.10 per public share, allowing the Company to extend the period of time it has to consummate its initial Business Combination by three months from May 18, 2023 to August 18, 2023. On August 18, 2023, the Company caused to be deposited $ 125,000 into the Company’s Trust Account, allowing the Company to extend the period of time it has to consummate its initial Business Combination from August 18, 2023 to September 18, 2023. On September 26, 2023, the Company caused to be deposited $ 125,000 into the Company’s Trust Account, allowing the Company to extend the period of time it has to consummate its initial Business Combination from September 18, 2023 to October 18, 2023. On October 18, 2023, the Company caused to be deposited $ 125,000 into the Company’s Trust Account, allowing the Company to extend the period of time it has to consummate its initial Business Combination from October 18, 2023 to November 18, 2023. On November 18, 2023, the Company caused to be deposited $ 125,000 into the Company’s Trust Account, allowing the Company to extend the period of time it has to consummate its initial Business Combination from November 18, 2023 to December 18, 2023. On December 18, 2023, the Company caused to be deposited $ 125,000 into the Company’s Trust Account, allowing the Company to extend the period of time it has to consummate its initial Business Combination from December 18, 2023 to January 18, 2023. On February 18, 2024, the Company caused to be deposited $ 50,000 50,000 50,000 50,000 50,000 50,000 50,000 50,000 50,000 On November 20, 2024, the Company caused to be deposited $ 37,744 37,744 37,744 As of September 30, 2024 and December 31, 2023, there was $ 3,300,000 2,925,000 As of January 27, 2025, there was approximately $ 3,400,000 Due from Sponsor As of September 30, 2024 and December 31, 2023 the Company had paid a total of $ 1,540,984 1,179,141 FUTURETECH II ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS Note 6 - Related Party Transactions (Continued) Administrative Support Agreement Commencing on the date the Units are first listed on Nasdaq, the Company has agreed to pay the Sponsor a total of $ 10,000 120,000 100,000 220,000 100,000 Representative Shares The Company issued to EF Hutton and/or its designees, 115,000 The representative shares have been deemed compensation by FINRA and are therefore subject to a lock-up for a period of 180 days immediately following the commencement of sales in the Initial Public Offering pursuant to Rule 5110(e)(1) of FINRA’s NASD Conduct Rules. Pursuant to FINRA Rule 5110(e)(1), these securities may not be sold, transferred, assigned, pledged or hypothecated or the subject of any hedging, short sale, derivative, put or call transaction that would result in the economic disposition of the securities by any person for a period of 180 days immediately following the effective date of the registration statement for the Initial Public Offering, nor may they be sold, transferred, assigned, pledged or hypothecated for a period of 180 days immediately following the commencement of sales in the Initial Public Offering except to any underwriter and selected dealer participating in the offering and their bona fide officers or partners, registered persons or affiliates or as otherwise permitted under Rule 5110(e)(2), and only if any such transferee agrees to the foregoing lock-up restrictions.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended	12 Months Ended
Commitments and Contingencies	Sep. 30, 2024	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6 - Commitments and Contingencies Registration Rights The holders of the insider shares, as well as the holders of the Private Placement Units (and underlying securities) and any securities issued in payment of working capital loans made to the Company, are entitled to registration rights pursuant to an agreement signed on the effective date of Initial Public Offering. The holders of a majority of these securities are entitled to make up to three demands that the Company register such securities. Notwithstanding anything to the contrary, the underwriters (and/or their designees) may only make a demand registration (i) on one occasion and (ii) during the five-year period beginning on the effective date of the Initial Public Offering. The holders of the majority of these securities can elect to exercise these registration rights at any time after the Company consummates a Business Combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. Notwithstanding anything to the contrary, the underwriters (and/or their designees) may participate in a “piggy-back” registration only during the seven-year period beginning on the effective date of the Initial Public Offering. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The underwriter was paid a cash underwriting discount of one and a half percent ( 1.50 1,725,000 3.50 3,450,000 115,000 Right of First Refusal For a period beginning on the closing of the Initial Public Offering and ending twenty-four (24) months from the closing of a Business Combination, the Company granted EF Hutton, division of Benchmark Investments, LLC a right of first refusal to act as lead-left book running manager and lead left manager for any and all future private or public equity, convertible and debt offerings during such period.	Note 7 - Commitments and Contingencies Registration Rights The holders of the insider shares, as well as the holders of the Private Placement Units (and underlying securities) and any securities issued in payment of working capital loans made to the Company, are entitled to registration rights pursuant to an agreement signed on the effective date of Initial Public Offering. The holders of a majority of these securities are entitled to make up to three demands that the Company register such securities. Notwithstanding anything to the contrary, the underwriters (and/or their designees) may only make a demand registration (i) on one occasion and (ii) during the five-year period beginning on the effective date of the Initial Public Offering. The holders of the majority of these securities can elect to exercise these registration rights at any time after the Company consummates a Business Combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. Notwithstanding anything to the contrary, the underwriters (and/or their designees) may participate in a “piggy-back” registration only during the seven-year period beginning on the effective date of the Initial Public Offering. The Company will bear the expenses incurred in connection with the filing of any such registration statements. FUTURETECH II ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS Note 7 - Commitments and Contingencies (Continued) Underwriting Agreement The underwriter was paid a cash underwriting discount of one and a half percent ( 1.50 1,725,000 3.50 3,450,000 115,000 Right of First Refusal For a period beginning on the closing of the Initial Public Offering and ending twenty-four (24) months from the closing of a Business Combination, the Company granted EF Hutton, division of Benchmark Investments, LLC a right of first refusal to act as lead-left book running manager and lead left manager for any and all future private or public equity, convertible and debt offerings during such period.

Stockholders_ Deficit

Stockholders’ Deficit	9 Months Ended	12 Months Ended
Stockholders’ Deficit	Sep. 30, 2024	Dec. 31, 2023
Equity [Abstract]
Stockholders’ Deficit	Note 7 - Stockholders’ Deficit Preferred Shares 1,000,000 0.0001 no Class A Common Stock 100,000,000 0.0001 Holders of the Company’s Class A common stock are entitled to one vote for each share. 635,075 115,000 2,319,435 5,556,350 Note 7 - Stockholders’ Deficit (Continued) Class B Common Stock - 10,000,000 0.0001 Holders of the Company’s Class B common stock are entitled to one vote for each share. 2,875,000 At the Third Extension Meeting held on November 18, 2024, stockholders approved by requisite votes to amend the Charter to provide for the right of the holders of Class B common stock, par value $ 0.0001 0.0001 The Converted Class A Common Stock remain as founders’ shares (the “Founders’ Shares) and is not subject to redemption and will be subject to transfer restrictions. Only holders of the Class B common stock and the Founders’ Shares will have the right to vote on the election of directors prior to the Business Combination. Holders of Class A common stock and holders of Class B common stock will vote together as a single class on all matters submitted to a vote of the Company’s stockholders except as otherwise required by law. In connection with the Company’s initial Business Combination, the Company may enter into a shareholders agreement or other arrangements with the shareholders of the target or other investors to provide for voting or other corporate governance arrangements that differ from those in effect upon completion of the Initial Public Offering. The shares of Class B common stock will automatically convert into Class A common stock at the time of a Business Combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts issued in the Initial Public Offering and related to the closing of a Business Combination, the ratio at which shares of Class B common stock shall convert into shares of Class A common stock will be adjusted (unless the holders of a majority of the then-outstanding shares of Class B common stock agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of shares of Class A common stock issuable upon conversion of all shares of Class B common stock will equal, in the aggregate, on an as-converted basis, 20 Warrants The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants is then effective and a current prospectus relating to those shares of Class A common stock is available, subject to the Company satisfying its obligations with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of residence of the exercising holder, or an exemption from registration is available. The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of a Business Combination, the Company will use its commercially reasonable efforts to file, and within 60 business days following a Business Combination to have declared effective, a registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed. Notwithstanding the above, if the Class A common stock is at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. Note 7 - Stockholders’ Deficit (Continued) Redemption of Warrants When the Price per Share of Class A Common Stock Equals or Exceeds $18.00 ● in whole and not in part; ● at a price of $ 0.01 ● upon a minimum of 30 days’ prior written notice of redemption, or the 30-day redemption period to each warrant holder; and ● if, and only if, the last reported sale price of the Class A common stock equals or exceeds $ 18.00 If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. If the Company calls the Public Warrants for redemption, as described above, its management will have the option to require any holder that wishes to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of shares of common stock issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the required period and the Company liquidates the funds held in the Trust Account, holders of Public Warrants will not receive any of such funds with respect to their Public Warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such Public Warrants. Accordingly, the Public Warrants may expire worthless. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering.	Note 8 - Stockholders’ Equity (Deficit) Stockholders’ Deficit Preferred Shares 1,000,000 0.0001 no Class A Common Stock 100,000,000 0.0001 Holders of the Company’s Class A common stock are entitled to one vote for each share. 635,075 115,000 5,556,350 11,500,000 Class B Common Stock - 10,000,000 0.0001 Holders of the Company’s Class B common stock are entitled to one vote for each share. 2,875,000 375,000 Only holders of the Class B common stock will have the right to vote on the election of directors prior to the Business Combination. Holders of Class A common stock and holders of Class B common stock will vote together as a single class on all matters submitted to a vote of the Company’s stockholders except as otherwise required by law. In connection with the Company’s initial Business Combination, the Company may enter into a shareholders agreement or other arrangements with the shareholders of the target or other investors to provide for voting or other corporate governance arrangements that differ from those in effect upon completion of the Initial Public Offering. The shares of Class B common stock will automatically convert into Class A common stock at the time of a Business Combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts issued in the Initial Public Offering and related to the closing of a Business Combination, the ratio at which shares of Class B common stock shall convert into shares of Class A common stock will be adjusted (unless the holders of a majority of the then-outstanding shares of Class B common stock agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of shares of Class A common stock issuable upon conversion of all shares of Class B common stock will equal, in the aggregate, on an as-converted basis, 20 FUTURETECH II ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS Note 8 - Stockholders’ Equity (Deficit) (Continued) Warrants The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants is then effective and a current prospectus relating to those shares of Class A common stock is available, subject to the Company satisfying its obligations with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of residence of the exercising holder, or an exemption from registration is available. The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of a Business Combination, the Company will use its commercially reasonable efforts to file, and within 60 business days following a Business Combination to have declared effective, a registration statement covering the issuance of the shares of Class A common stock issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed. Notwithstanding the above, if the Class A common stock is at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. Redemption of Warrants When the Price per Share of Class A Common Stock Equals or Exceeds $18.00 ● in whole and not in part; ● at a price of $ 0.01 ● upon a minimum of 30 days’ prior written notice of redemption, or the 30-day redemption period to each warrant holder; and ● if, and only if, the last reported sale price of the Class A common stock equals or exceeds $ 18.00 If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. If the Company calls the Public Warrants for redemption, as described above, its management will have the option to require any holder that wishes to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of shares of common stock issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company is unable to complete a Business Combination within the required period and the Company liquidates the funds held in the Trust Account, holders of Public Warrants will not receive any of such funds with respect to their Public Warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such Public Warrants. Accordingly, the Public Warrants may expire worthless. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering.

Fair Value Measurements

Fair Value Measurements	9 Months Ended	12 Months Ended
Fair Value Measurements	Sep. 30, 2024	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	NOTE 8 - Fair Value Measurements The Company follows the guidance in ASC 820 for its financial assets that are re-measured and reported at fair value at each reporting period. The following table presents information about the Company’s assets that are measured at fair value at September 30, 2024 and December 31, 2023, and indicates the Fair Value Hierarchy of the valuation inputs the Company utilized to determine such fair value: Schedule of Assets Measured at Fair Value Description: Level September 30, 2024 December 31, 2023 Assets: Interest Bearing Bank Demand Deposit held in trust account 1 $ 26,932,536 $ 61,839,164	NOTE 9. FAIR VALUE MEASUREMENTS Fair Value Measurements The Company follows the guidance in ASC 820 for its financial assets that are re-measured and reported at fair value at each reporting period. The following table presents information about the Company’s assets that are measured at fair value at December 31, 2023 and 2022, and indicates the Fair Value Hierarchy of the valuation inputs the Company utilized to determine such fair value: Schedule of Assets Measured at Fair Value December 31, December 31, Description: Level 2023 2022 Assets: Marketable securities held in trust account 1 $ 61,839,164 $ 118,976,585 FUTURETECH II ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS

Subsequent Events

Subsequent Events	9 Months Ended	12 Months Ended
Subsequent Events	Sep. 30, 2024	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 9 – Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date. Based upon this review the Company identified the following subsequent events, that would have required adjustment or disclosure in the unaudited condensed financial statements. Extension of Combination Period On November 18, 2024, the Company held the Third Extension Meeting at which the Company’s stockholders approved the Third Charter Amendment by requisite votes, (i) giving the Company the right to extend the deadline of Combination Period from November 18, 2024 to August 18, 2025, provided that the Sponsor (or its affiliates or permitted designees) will deposit into Trust Account an aggregate amount equal to $ 0.05 In connection with the Third Extension Meeting, holders of 1,564,549 Class B Common Stock Immediately following the Third Extension Meeting and filing of the Third Charter Amendment with the Secretary of State of the State of Delaware, on November 22, 2024, the holders of shares of Class B Common Stock unanimously elected to convert all of their shares of Class B Common Stock to shares of Class A Common Stock on a one-to-one basis. On February 4, 2025, the Company and the holders of these shares effected such conversions by sending the Transfer Agent required instruction document. As a result, all of 2,875,000 2,875,000 0 Extension Loans On October 18, 2024, the Company caused to be deposited $ 50,000 37,744 37,744 37,744 Overpayment in Redemption of the First Extension Redeeming Stockholders and Second Extension Redeeming Shareholders In connection with the First Extension Meeting, on August 22, 2023, a redemption payment was made by Continental Stock Transfer & Trust Company (“CST”), as trustee of the Trust Account, to the First Extension Redeeming Stockholders at a rate of approximately $ 10.81 10.74 0.07 In connection with the Second Extension Meeting, on February 22, 2024, a redemption payment was made by CST, as trustee of the Trust Account, to the Second Extension Redeeming Stockholders at a rate of approximately $ 11.21 11.10 0.11 The First Extension Redeeming Shareholders and the Second Extension Redeeming Stockholders are in the process of being notified of this situation and are being instructed to return the First Extension Overpayment Amount and the Second Extension Overpayment Amount to CST. In light of the above, the Company amended and restated its prior financial statements during the Affected Period as disclosed in its Current Report on Form 8-K filed with the SEC on December 13, 2024. The aggregate amount of the First Extension Overpayment Amount and the Second Extension Overpayment Amount is reflected in the Company’s financial statements as Due from the Sponsor.	Note 11 – Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date. Based upon this review the Company identified the following subsequent events, that would have required adjustment or disclosure in the unaudited condensed financial statements. Extension of Combination Period On November 18, 2024, the Company held the Third Extension Meeting at which the Company’s stockholders approved the Third Charter Amendment by requisite votes, (i) giving the Company the right to extend the deadline of Combination Period from November 18, 2024 to August 18, 2025, provided that the Sponsor (or its affiliates or permitted designees) will deposit into Trust Account an aggregate amount equal to $ 0.05 In connection with the Third Extension Meeting, holders of 1,564,549 Class B Common Stock Immediately following the Third Extension Meeting and filing of the Third Charter Amendment with the Secretary of State of the State of Delaware, on November 22, 2024, the holders of shares of Class B Common Stock unanimously elected to convert all of their shares of Class B Common Stock to shares of Class A Common Stock on a one-to-one basis. As a result, all of 2,875,000 2,875,000 0 Extension Loans On October 18, 2024, the Company caused to be deposited $ 50,000 37,744 37,744 37,744 Overpayment in Redemption of the First Extension Redeeming Stockholders and Second Extension Redeeming Shareholders In connection with the First Extension Meeting, on August 22, 2023, a redemption payment was made by Continental Stock Transfer & Trust Company (“CST”), as trustee of the Trust Account, to the First Extension Redeeming Stockholders at a rate of approximately $ 10.81 10.74 0.07 In connection with the Second Extension Meeting, on February 22, 2024, a redemption payment was made by CST, as trustee of the Trust Account, to the Second Extension Redeeming Stockholders at a rate of approximately $ 11.21 11.10 0.11 The First Extension Redeeming Shareholders and the Second Extension Redeeming Stockholders are in the process of being notified of this situation and are being instructed to return the First Extension Overpayment Amount and the Second Extension Overpayment Amount to CST. In light of the above, the Company amended and restated its prior financial statements during the Affected Period as disclosed in its Current Report on Form 8-K filed with the SEC on December 13, 2024. The aggregate amount of the First Extension Overpayment Amount and the Second Extension Overpayment Amount is reflected in the Company’s unaudited condensed financial statements in this Form 10-Q as Due from the Sponsor.

Restatement of Previously Issue

Restatement of Previously Issued Financial Statements	12 Months Ended
Restatement of Previously Issued Financial Statements	Dec. 31, 2023
Accounting Changes and Error Corrections [Abstract]
Restatement of Previously Issued Financial Statements	Note 2 – Restatement of Previously Issued Financial Statements In connection with (i) preparation of the Proxy dated October 31, 2024 which included the estimated redemption price for redeeming stockholders related to the Third Extension Meeting, which was held on November 18, 2024, and (ii) the preparation of the unaudited condensed financial statements of the Company as of and for the three and nine months ended September 30, 2024, the Company determined that there were errors for the accounting of Due from Sponsor, Common stock subject to possible redemption, accumulated deficit (capital contribution), notes payable and the redemption price of the Common stock subject to possible redemption in the previously issued December 31, 2023 financial statements. In accordance with SEC Staff Accounting Bulletin No. 99, “Materiality,” and SEC Staff Accounting Bulletin No. 108, “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements,” the Company determined that the errors were material to its previously issued financial statements. Therefore, the Company concluded that the previously issued financial statements should be restated. The following tables summarize the effect of the restatement on each financial statement line items as of the dates, and for the period, indicated: December 31, 2023 Schedule of Effect of the Restatement As Previously Reported Adjustments As Restated Balance Sheet Due from Sponsor $ 731,912 $ 447,229 $ 1,179,141 Total Current Assets $ 938,533 $ 447,229 $ 1,385,762 Total Assets $ 62,777,697 $ 447,229 $ 63,224,926 Note Payable - Sponsor $ - $ 2,925,000 $ 2,925,000 Total Current Liabilities $ 2,122,202 $ 2,925,000 $ 5,047,201 Total Liabilities $ 5,572,202 $ 2,925,000 $ 8,497,201 Class A Common Stock Subject to Possible Redemption $ 60,532,197 $ 694,606 $ 61,226,803 Accumulated deficit $ (3,327,054 ) $ (3,172,376 ) $ (6,499,430 ) Total Stockholder’s Equity $ (3,326,702 ) $ (3,172,376 ) $ (6,499,078 ) Total Liabilities and Stockholder’s Equity $ 62,777,697 $ 447,229 $ 63,224,926 Statement of Cash Flows Capital Contribution from Sponsor $ 3,938,297 $ (2,925,000 ) $ 1,013,297 Proceeds from Sponsor Note $ - $ 2,925,000 $ 2,925,000 Redemption price $ 10.90 $ 0.12 $ 11.02 FUTURETECH II ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 10 – Income Taxes The Company’s deferred tax assets are as follows at December 31, 2023 and 2022: Schedule of Deferred Taxes Asset (Liability) December 31, 2023 December 31, 2022 Deferred tax asset Start-up costs $ 162,267 $ 98,101 Total deferred tax asset 162,267 98,101 Valuation Allowance (162,267 ) (98,101 ) Deferred tax asset, net of allowance $ — $ — The income tax provision (benefit) consists of the following for the year ended December 31,2023 and 2022: Schedule of Income Tax Provision Benefit For the Year Ended For the Year Ended December 31, 2023 December 31, 2022 Federal Current $ 979,344 $ 310,259 Deferred 162,267 98,101 State and Local: Current — — Deferred — — Change in valuation allowance (162,267 ) (98,101 ) Income tax provision $ 979,344 $ 310,259 In assessing the realization of the deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. For the years ended December 31, 2023 and 2022, the change in the valuation allowance was $ 162,267 98,101 Schedule of Effective Income Tax Rate Reconciliation For the Year Ended For the Year Ended December 31, 2023 December 31, 2022 U.S. federal statutory rate (21.0 )% (21.0 )% Valuation allowance (4.2 )% (9.8 )% Income tax provision (25.2 )% (30.8 )%

Summary of Significant Accoun_2

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Sep. 30, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Schedule of Common Stock Reflected on Balance Sheet Reconciled	As of September 30, 2024 and December 31, 2023, the shares of common stock reflected on the unaudited condensed balance sheets are reconciled in the following table. Schedule of Common Stock Reflected on Balance Sheet Reconciled Ending Balance as of December 31, 2022 $ 118,466,326 Redemption of Class A common stock (64,238,888 ) Remeasurement of carrying value to redemption value 6,552,136 Due from Sponsor 447,229 Ending Balance as of December 31, 2023 61,226,803 Redemption of Class A common stock (36,281,990 ) Remeasurement of carrying value to redemption value 615,511 Due from Sponsor 361,843 Ending Balance as of March 31, 2024 25,922,167 Remeasurement of carrying value to redemption value 340,437 Ending Balance as of June 30, 2024 26,262,604 Remeasurement of carrying value to redemption value 343,991 Ending Balance as of September 30, 2024 $ 26,606,595	As of December 31, 2023 (restated) and 2022, the shares of common stock reflected on the balance sheet are reconciled in the following table. Schedule of Common Stock Reflected on Balance Sheet Reconciled Gross Proceeds $ 115,000,000 Less: Proceeds allocated to public warrants (1,067,463 ) Temporary equity offering costs (5,635,551 ) Plus: Remeasurement of carrying value to redemption value 9,003,014 Ending Balance as of March 31, 2022 117,300,000 Remeasurement of carrying value to redemption value 1,166,326 Ending Balance as of December 31, 2022 118,466,326 Redemption of Class A common stock (64,238,888 ) Remeasurement of carrying value to redemption value 6,552,136 Due from Sponsor 447,229 Ending Balance as of December 31, 2023 (restated) $ 61,226,803
Schedule of Basic and Diluted Net Income (Loss) Per Common Share	The following table reflects the calculation of basic and diluted net income (loss) per share (in dollars, except per share amounts): Schedule of Basic and Diluted Net Income (Loss) Per Common Share Three Months Ended Three Months Ended September 30, 2024 September 30, 2023 Redeemable Non-redeemable Redeemable Non-redeemable Basic and diluted net income (loss) per share of common stock Numerator: Interest $ 287,584 $ - $ 1,232,507 $ - Less: Allocation of expenses (163,413 ) (247,298 ) (406,478 ) (164,803 ) Less: Accretion of carrying value to redemption value (649,442 ) - - - Total $ (525,271 ) $ (247,298 ) $ 826,029 $ (164,803 ) Basic and diluted net income (loss) per share of common stock $ (0.23 ) $ (0.07 ) $ 0.10 $ (0.05 ) Nine Months Ended Nine Months Ended September 30, 2024 September 30, 2023 Redeemable Non-redeemable Redeemable Non-redeemable Basic and diluted net income (loss) per share of common stock Numerator: Interest $ 1,107,012 $ - $ 3,989,390 $ - Less: Allocation of expenses (513,195 ) (631,822 ) (1,263,723 ) (420,768 ) Less: Accretion of carrying value to redemption value (649,442 ) - - - Total $ (55,625 ) $ (631,822 ) $ 2,725,667 $ (420,768 ) Basic and diluted net income (loss) per share of common stock $ (0.02 ) $ (0.18 ) $ 0.26 $ (0.12 )	The following table reflects the calculation of basic and diluted net income (loss) per share (in dollars, except per share amounts): Schedule of Basic and Diluted Net Income (Loss) Per Common Share Year Ended Year Ended December 31, 2023 December 31, 2022 Redeemable Non-redeemable Redeemable Non-redeemable Basic and diluted net income (loss) per share of common stock Numerator: Interest $ 4,953,545 $ - $ 1,676,585 $ - Less: Allocation of net income (loss), as adjusted (2,982,080 ) (560,177 ) (1,323,201 ) (228,369 ) Total $ (1,971,465 ) $ (560,177 ) $ 353,384 $ (228,369 ) Basic and diluted net income (loss) per share of common stock $ 0.21 $ (0.16 ) $ 0.03 $ (0.07 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended	12 Months Ended
Fair Value Measurements (Tables)	Sep. 30, 2024	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Assets Measured at Fair Value	The following table presents information about the Company’s assets that are measured at fair value at September 30, 2024 and December 31, 2023, and indicates the Fair Value Hierarchy of the valuation inputs the Company utilized to determine such fair value: Schedule of Assets Measured at Fair Value Description: Level September 30, 2024 December 31, 2023 Assets: Interest Bearing Bank Demand Deposit held in trust account 1 $ 26,932,536 $ 61,839,164	The following table presents information about the Company’s assets that are measured at fair value at December 31, 2023 and 2022, and indicates the Fair Value Hierarchy of the valuation inputs the Company utilized to determine such fair value: Schedule of Assets Measured at Fair Value December 31, December 31, Description: Level 2023 2022 Assets: Marketable securities held in trust account 1 $ 61,839,164 $ 118,976,585

Restatement of Previously Iss_2

Restatement of Previously Issued Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2023
Accounting Changes and Error Corrections [Abstract]
Schedule of Effect of the Restatement	The following tables summarize the effect of the restatement on each financial statement line items as of the dates, and for the period, indicated: December 31, 2023 Schedule of Effect of the Restatement As Previously Reported Adjustments As Restated Balance Sheet Due from Sponsor $ 731,912 $ 447,229 $ 1,179,141 Total Current Assets $ 938,533 $ 447,229 $ 1,385,762 Total Assets $ 62,777,697 $ 447,229 $ 63,224,926 Note Payable - Sponsor $ - $ 2,925,000 $ 2,925,000 Total Current Liabilities $ 2,122,202 $ 2,925,000 $ 5,047,201 Total Liabilities $ 5,572,202 $ 2,925,000 $ 8,497,201 Class A Common Stock Subject to Possible Redemption $ 60,532,197 $ 694,606 $ 61,226,803 Accumulated deficit $ (3,327,054 ) $ (3,172,376 ) $ (6,499,430 ) Total Stockholder’s Equity $ (3,326,702 ) $ (3,172,376 ) $ (6,499,078 ) Total Liabilities and Stockholder’s Equity $ 62,777,697 $ 447,229 $ 63,224,926 Statement of Cash Flows Capital Contribution from Sponsor $ 3,938,297 $ (2,925,000 ) $ 1,013,297 Proceeds from Sponsor Note $ - $ 2,925,000 $ 2,925,000 Redemption price $ 10.90 $ 0.12 $ 11.02 FUTURETECH II ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Deferred Taxes Asset (Liability)	The Company’s deferred tax assets are as follows at December 31, 2023 and 2022: Schedule of Deferred Taxes Asset (Liability) December 31, 2023 December 31, 2022 Deferred tax asset Start-up costs $ 162,267 $ 98,101 Total deferred tax asset 162,267 98,101 Valuation Allowance (162,267 ) (98,101 ) Deferred tax asset, net of allowance $ — $ —
Schedule of Income Tax Provision Benefit	The income tax provision (benefit) consists of the following for the year ended December 31,2023 and 2022: Schedule of Income Tax Provision Benefit For the Year Ended For the Year Ended December 31, 2023 December 31, 2022 Federal Current $ 979,344 $ 310,259 Deferred 162,267 98,101 State and Local: Current — — Deferred — — Change in valuation allowance (162,267 ) (98,101 ) Income tax provision $ 979,344 $ 310,259
Schedule of Effective Income Tax Rate Reconciliation	Schedule of Effective Income Tax Rate Reconciliation For the Year Ended For the Year Ended December 31, 2023 December 31, 2022 U.S. federal statutory rate (21.0 )% (21.0 )% Valuation allowance (4.2 )% (9.8 )% Income tax provision (25.2 )% (30.8 )%

Description of Organization a_2

Description of Organization and Business Operations, Going Concern and Basis of Presentation (Details Narrative) - USD ($)					9 Months Ended	12 Months Ended
	Nov. 18, 2024	Oct. 01, 2024	Feb. 18, 2022	Feb. 16, 2022	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022	Aug. 31, 2023	Aug. 16, 2022
Gross proceeds from issuance of public offering			$ 117,300,000			$ 117,300,000
Proceeds from private placement							$ 5,200,750
Shares issued, price per share			$ 10			$ 10
Deferred underwriting fees					$ 3,450,000	$ 3,450,000	3,450,000
Cash					1,883	17,578	262,756
Working capital deficit					$ 4,638,328	3,661,439
Percentage of assets held in trust required					80%
Percentage of post transaction ownership required					50%
Interest expense					$ 100,000	$ 100,000
Percentage of exercise tax to be imposed									1%
Public shares to be redeemed if business combination is not completed						50%
Common stock subject to possible redemption per share								$ 10.74
Due from sponsor					$ 1,540,984	$ 1,179,141
Liquidity and Managements Plans [Member]
Cash						17,578	262,756
Working capital						$ 3,661,439	367,265
Revision of Prior Period, Adjustment [Member]
Due from sponsor								$ 447,229
Subsequent Event [Member]
Stock issued during period new issue, shares	1,564,549
Share price	$ 0.05
Current yield on the funds held in the trust account percentage		3.72%
IPO [Member]
Sale of stock, number of shares issued			11,500,000
Gross proceeds from issuance of public offering			$ 115,000,000
Shares issued, price per share					$ 10.20	$ 10.20
Cash held outside of trust account					$ 700,000	$ 700,000
Cash						17,578	262,756
Working capital						$ 3,661,439	$ 367,265
Private Placement [Member]
Stock issued during period new issue, shares			520,075
Private Placement [Member] \| Sponsor [Member]
Stock issued during period new issue, shares				520,075		520,075
Share price			$ 10	$ 10		$ 10
Proceeds from private placement			$ 5,200,750	$ 5,200,750		$ 5,200,750
Over-Allotment Option [Member]
Offering cost					5,688,352	5,688,352
Cash underwriting fees					1,725,000	1,725,000
Deferred underwriting fees					3,450,000	3,450,000
Other deferred costs					$ 513,352	$ 513,352

Schedule of Common Stock Reflec

Schedule of Common Stock Reflected on Balance Sheet Reconciled (Details) - USD ($)		3 Months Ended				9 Months Ended		12 Months Ended
	Feb. 18, 2022	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Mar. 31, 2022	Sep. 30, 2024	Dec. 31, 2022	Dec. 31, 2023
Gross Proceeds	$ 117,300,000							$ 117,300,000
Common Class A [Member]
Balance		$ 26,262,604	$ 25,922,167	$ 61,226,803		$ 61,226,803	$ 117,300,000	118,466,326
Redemption of Class A common stock				(36,281,990)				(64,238,888)
Remeasurement of carrying value to redemption value		343,991	340,437	615,511				6,552,136
Due from Sponsor				361,843		361,843		447,229
Balance		$ 26,606,595	$ 26,262,604	$ 25,922,167	$ 117,300,000	26,606,595	118,466,326	61,226,803
Gross Proceeds					115,000,000
Proceeds allocated to public warrants					(1,067,463)
Temporary equity offering costs					(5,635,551)
Remeasurement of carrying value to redemption value					$ 9,003,014	$ 36,281,990	$ 1,166,326	$ 6,552,136

Schedule of Basic and Diluted N

Schedule of Basic and Diluted Net Income (Loss) Per Common Share (Details) - USD ($)	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Allocation of net income (loss), as adjusted	$ (123,127)	$ (44,457)	$ 129,577	$ 661,226	$ 836,383	$ 807,289	$ (38,005)	$ 2,304,899	$ 2,911,502	$ 700,015
Redeemable [Member]
Basic net income (loss) per share of common stock Numerator: Interest	287,584			1,232,507			1,107,012	3,989,390	4,953,545	1,676,585
Diluted net income (loss) per share of common stock Numerator: Interest	287,584			1,232,507			1,107,012	3,989,390	4,953,545	1,676,585
Allocation of net income (loss), as adjusted	$ (163,413)			$ (406,478)			$ (513,195)	$ (1,263,723)	$ (2,982,080)	$ (1,323,201)
Less: Accretion of carrying value to redemption value	(649,442)						(649,442)
Total	$ (525,271)			$ 826,029			$ (55,625)	$ 2,725,667	$ (1,971,465)	$ (353,384)
Basic net income (loss) per share of common stock	$ (0.23)			$ 0.10			$ (0.02)	$ 0.26	$ 0.21	$ 0.03
Diluted net income (loss) per share of common stock	$ (0.23)			$ 0.10			$ (0.02)	$ 0.26	$ 0.21	$ 0.03
Total	$ 525,271			$ (826,029)			$ 55,625	$ (2,725,667)	$ 1,971,465	$ 353,384
Non Redeemable [Member]
Basic net income (loss) per share of common stock Numerator: Interest
Diluted net income (loss) per share of common stock Numerator: Interest
Allocation of net income (loss), as adjusted	$ (247,298)			$ (164,803)			$ (631,822)	$ (420,768)	$ (560,177)	$ (228,369)
Less: Accretion of carrying value to redemption value
Total	$ (247,298)			$ (164,803)			$ (631,822)	$ (420,768)	$ (560,177)	$ (228,369)
Basic net income (loss) per share of common stock	$ (0.07)			$ (0.05)			$ (0.18)	$ (0.12)	$ (0.16)	$ (0.07)
Diluted net income (loss) per share of common stock	$ (0.07)			$ (0.05)			$ (0.18)	$ (0.12)	$ (0.16)	$ (0.07)
Total	$ 247,298			$ 164,803			$ 631,822	$ 420,768	$ 560,177	$ 228,369

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended
	Feb. 18, 2022	Mar. 31, 2024	Mar. 31, 2022	Sep. 30, 2024	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Aug. 31, 2023	Aug. 16, 2022
Cash FDIC insured amount				$ 250,000		$ 250,000
Cash FDIC insured amount in excess				0		0
SIPC insured amount for cash				250,000
SIPC insured amount for securities				250,000
SIPC insured amount for securities in excess				26,682,536		61,589,164
Cash				1,883	$ 262,756	17,578	$ 262,756
Cash equivalents				0		0
Proceeds from issuance initial public offering	$ 117,300,000					$ 117,300,000
Shares issued price per share	$ 10					$ 10
Marketable securities held in trust account				26,932,536	118,976,585	$ 61,839,164	118,976,585
Payment of offering cost							316,640
Unrecognized tax benefits				0		0
Unrecognized tax benefits, income tax penalties and interest accrued				0		0
Percentage of exercise tax to be imposed									1%
Due from sponsor				1,540,984		1,179,141
Revision of Prior Period, Adjustment [Member]
Due from sponsor								$ 447,229
Common Class A [Member]
Proceeds from issuance initial public offering			$ 115,000,000
Common stock subject to possible redemption amount				26,606,595	118,466,326	61,226,803	118,466,326
Common stock subject to possible redemption amount				34,620,208		57,239,523
Common stock subject to possible redemption is due to a redemption			$ 9,003,014	36,281,990	1,166,326	6,552,136
Remeasurement adjustment				1,299,939		6,552,136
Due from sponsor		$ 361,843		$ 361,843		447,229
Due to common stock subject to possible redemption amount		$ 36,281,990				64,238,888
IPO [Member]
Cash					$ 262,756	$ 17,578	$ 262,756
Proceeds from issuance initial public offering	$ 115,000,000
Shares issued price per share				$ 10.20		$ 10.20
Payment of offering cost				$ 513,352		$ 513,352
Underwriter discount				$ 1,725,000		$ 1,725,000

Public Offering (Details Narrat

Public Offering (Details Narrative) - $ / shares		9 Months Ended	12 Months Ended
Public Offering (Details Narrative) - $ / shares	Feb. 18, 2022	Sep. 30, 2024	Dec. 31, 2023
Common Class A [Member]
Warrant exercise price		$ 11.50	$ 11.50
IPO [Member]
Stock issued during period for sale	11,500,000
IPO [Member] \| Underwriters Over-Allotment Option Exercised [Member]
Stock issued during period for sale		11,500,000	11,500,000
Sale of share price		$ 10	$ 10

Private Placement (Details Narr

Private Placement (Details Narrative) - USD ($)			12 Months Ended
Private Placement (Details Narrative) - USD ($)	Feb. 18, 2022	Feb. 16, 2022	Dec. 31, 2023	Dec. 31, 2022
Subsidiary, Sale of Stock [Line Items]
Proceeds from private placement				$ 5,200,750
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Private placement initial public offering	520,075
Private Placement [Member] \| Sponsor [Member]
Subsidiary, Sale of Stock [Line Items]
Private placement initial public offering		520,075	520,075
Share price	$ 10	$ 10	$ 10
Proceeds from private placement	$ 5,200,750	$ 5,200,750	$ 5,200,750

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)			3 Months Ended				9 Months Ended		12 Months Ended
Related Party Transactions (Details Narrative) - USD ($)	Nov. 18, 2024	Oct. 08, 2021	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Jan. 27, 2025	Jan. 18, 2025	Dec. 18, 2024	Nov. 20, 2024	Oct. 18, 2024	Sep. 18, 2024	Aug. 18, 2024	Jul. 18, 2024	Jun. 18, 2024	May 18, 2024	Apr. 18, 2024	Mar. 18, 2024	Feb. 18, 2024	Feb. 14, 2024	Jan. 18, 2024	Dec. 18, 2023	Nov. 18, 2023	Oct. 18, 2023	Sep. 26, 2023	Aug. 18, 2023	Aug. 17, 2023	May 17, 2023	Feb. 17, 2023	Feb. 18, 2022	Aug. 19, 2021
Stock issued during period, value, new issues										$ 115,000,000
Shares issued price per share									$ 10																									$ 10
Trust account deposit			$ 26,932,536				$ 26,932,536		$ 61,839,164	118,976,585
Other Receivables			1,540,984				1,540,984		1,179,141
Payment to sponser							10,000		10,000
Administrative expenses									120,000	100,000
Accounts payable and accrued expenses			611,188				$ 611,188		295,137	130,225
Capital contribution			$ 79,399	$ 309,391	$ 48,666	$ 8,733			1,013,297
Gain on forgiveness of debt									144,443
Administrative Support Agreement [Member]
Accounts payable and accrued expenses									$ 220,000	100,000
IPO [Member]
Shares issued price per share			$ 10.20				$ 10.20		$ 10.20
Administrative Expenses [Member]
Accounts payable and accrued expenses			$ 310,000				$ 310,000		$ 220,000
Related Party [Member]
Administrative expenses			30,000			$ 30,000	$ 90,000	$ 90,000	$ 120,000	$ 100,000
EF Hutton and/or its Designees [Member] \| IPO [Member]
Sale of units in Initial Public Offering, net of offering costs, shares									115,000
Subsequent Event [Member]
Sale of units in Initial Public Offering, net of offering costs, shares	1,564,549
Share price	$ 0.05
Unsecured Promissory Note [Member]
Debt instrument description							The note is non-interest bearing and payable on the earlier of (i) March 31, 2022 or (ii) the consummation of the Initial Public Offering. As of September 30, 2024 and December 31, 2023, there is no amount outstanding pursuant to the promissory note, respectively.		The note is non-interest bearing and payable on the earlier of (i) March 31, 2022 or (ii) the consummation of the Initial Public Offering.
Unsecured Promissory Note [Member] \| Maximum [Member]
Principal amount																																			$ 300,000
Extension Loan [Member]
Trust account deposit									$ 125,000							$ 50,000	$ 50,000	$ 50,000	$ 50,000	$ 50,000	$ 50,000	$ 50,000	$ 50,000	$ 50,000	$ 125,000	$ 125,000	$ 125,000	$ 125,000	$ 125,000	$ 125,000	$ 125,000	$ 1,150,000	$ 1,150,000
Share price									$ 0.04															$ 0.03							$ 0.04	$ 0.10	$ 0.10
Loan outstanding			$ 3,300,000				$ 3,300,000		$ 2,925,000
Extension Loan [Member] \| Subsequent Event [Member]
Trust account deposit												$ 37,744	$ 37,744	$ 37,744	$ 50,000
Share price	0.05
Loan outstanding											$ 3,400,000
Affiliate Sponsor [Member]
Loan price per share			$ 10				$ 10		$ 10
Affiliate Sponsor [Member] \| Maximum [Member]
Convertible notes			$ 1,500,000				$ 1,500,000		$ 1,500,000
Common Class B [Member]
Percentage of issued and outstanding shares after initial public offering		20%
Sale of stock price per share		$ 12
Common stock, par value	0.0001		$ 0.0001				$ 0.0001		$ 0.0001	$ 0.0001
Common Class B [Member] \| Sponsor [Member]
Sale of units in Initial Public Offering, net of offering costs, shares		2,875,000
Stock issued during period, value, new issues		$ 25,000
Shares issued price per share		$ 0.009
Number of option issued for forfeiture		375,000
Percentage of issued and outstanding shares after initial public offering		20%
Sale of stock price per share		$ 12
Common Class A [Member]
Common stock, par value	$ 0.0001		$ 0.0001				$ 0.0001		$ 0.0001	$ 0.0001
Common Class A [Member] \| EF Hutton and/or its Designees [Member] \| IPO [Member]
Sale of units in Initial Public Offering, net of offering costs, shares							115,000		115,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)		3 Months Ended	9 Months Ended	12 Months Ended
Commitments and Contingencies (Details Narrative) - USD ($)	Feb. 18, 2022	Mar. 31, 2022	Sep. 30, 2024	Dec. 31, 2023
Gross proceeds from issuance of public offering	$ 117,300,000			$ 117,300,000
Common Class A [Member]
Gross proceeds from issuance of public offering		$ 115,000,000
IPO [Member]
Gross proceeds from issuance of public offering	$ 115,000,000
IPO [Member] \| EF Hutton and/or its Designees [Member]
Sale of units in Initial Public Offering, net of offering costs, shares				115,000
IPO [Member] \| EF Hutton and/or its Designees [Member] \| Common Class A [Member]
Sale of units in Initial Public Offering, net of offering costs, shares			115,000	115,000
Underwriters Agreement [Member] \| IPO [Member]
Percentage of underwriting discount			1.50%	1.50%
Gross proceeds from issuance of public offering			$ 1,725,000	$ 1,725,000
Underwriters Agreement [Member] \| IPO [Member] \| Underwritters [Member]
Gross proceeds from issuance of public offering			$ 3,450,000	$ 3,450,000
Percent of underwriting deferred fee			3.50%	3.50%

Stockholders_ Deficit (Details

Stockholders’ Deficit (Details Narrative)	9 Months Ended	12 Months Ended
Stockholders’ Deficit (Details Narrative)	Sep. 30, 2024 $ / shares shares	Dec. 31, 2023 $ / shares shares	Dec. 31, 2022 $ / shares shares	Nov. 18, 2024 $ / shares
Class of Stock [Line Items]
Preferred stock, shares authorized	1,000,000	1,000,000	1,000,000
Preferred stock, par value \| $ / shares	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares issued	0	0	0
Preferred stock, shares outstanding	0	0	0
Ordinary share conversion basis	0.20	20
Warrant [Member]
Class of Stock [Line Items]
Warrants price per share \| $ / shares	$ 0.01	$ 0.01
Common Class A [Member]
Class of Stock [Line Items]
Common stock, shares authorized	100,000,000	100,000,000	100,000,000
Common stock, par value \| $ / shares	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, voting rights	Holders of the Company’s Class A common stock are entitled to one vote for each share.	Holders of the Company’s Class A common stock are entitled to one vote for each share.
Common stock, shares issued	635,075	635,075	635,075
Common stock, shares outstanding	635,075	635,075	635,075
Common stock, shares	115,000	115,000	115,000
Temporary equity, shares issued	2,319,435	5,556,350	11,500,000
Temporary equity, shares oustanding	2,319,435	5,556,350	11,500,000
Warrants price per share \| $ / shares	$ 11.50	$ 11.50
Common stock subject to possible redemption shares		5,556,350	11,500,000
Common Class A [Member] \| Warrant [Member]
Class of Stock [Line Items]
Warrants price per share \| $ / shares	$ 18	$ 18
Common Class B [Member]
Class of Stock [Line Items]
Common stock, shares authorized	10,000,000	10,000,000	10,000,000
Common stock, par value \| $ / shares	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, voting rights	Holders of the Company’s Class B common stock are entitled to one vote for each share.	Holders of the Company’s Class B common stock are entitled to one vote for each share.
Common stock, shares issued	2,875,000	2,875,000	2,875,000
Common stock, shares outstanding	2,875,000	2,875,000	2,875,000
Common Class B [Member] \| Over-Allotment Option [Member]
Class of Stock [Line Items]
Share base compensation arrangement by share based payment award options forfeitures in period		375,000	375,000

Schedule of Assets Measured at

Schedule of Assets Measured at Fair Value (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities held in trust account	$ 26,932,536	$ 61,839,164	$ 118,976,585
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities held in trust account	$ 26,932,536	$ 61,839,164	$ 118,976,585

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Nov. 18, 2024	Jan. 28, 2025	Jan. 18, 2025	Dec. 18, 2024	Nov. 22, 2024	Nov. 20, 2024	Oct. 18, 2024	Sep. 30, 2024	Sep. 18, 2024	Aug. 18, 2024	Jul. 18, 2024	Jun. 18, 2024	May 18, 2024	Apr. 18, 2024	Mar. 18, 2024	Feb. 22, 2024	Feb. 18, 2024	Feb. 14, 2024	Jan. 18, 2024	Dec. 31, 2023	Dec. 18, 2023	Nov. 18, 2023	Oct. 18, 2023	Sep. 26, 2023	Aug. 31, 2023	Aug. 22, 2023	Aug. 18, 2023	Aug. 17, 2023	May 17, 2023	Feb. 17, 2023	Dec. 31, 2022
Subsequent Event [Line Items]
Trust account deposit								$ 26,932,536												$ 61,839,164											$ 118,976,585
Redemption per share																									$ 10.74
Extension Loan [Member]
Subsequent Event [Line Items]
Public shares redeemed per share																		$ 0.03		$ 0.04								$ 0.04	$ 0.10	$ 0.10
Trust account deposit									$ 50,000	$ 50,000	$ 50,000	$ 50,000	$ 50,000	$ 50,000	$ 50,000		$ 50,000	$ 50,000	$ 125,000	$ 125,000	$ 125,000	$ 125,000	$ 125,000	$ 125,000			$ 125,000	$ 125,000	$ 1,150,000	$ 1,150,000
Redemption per share																$ 11.21										$ 10.81
Redemption payment per share																11.10										10.74
Redemption overpayment per share																$ 0.11										$ 0.07
Common Class B [Member]
Subsequent Event [Line Items]
Common stock, shares issued								2,875,000												2,875,000											2,875,000
Common stock, shares outstanding								2,875,000												2,875,000											2,875,000
Common Class A [Member]
Subsequent Event [Line Items]
Common stock, shares issued								635,075												635,075											635,075
Common stock, shares outstanding								635,075												635,075											635,075
Redemption per share								$ 11.47												$ 11.02											$ 10.30
Subsequent Event [Member]
Subsequent Event [Line Items]
Public shares redeemed per share	$ 0.05
Sale of units in Initial Public Offering, net of offering costs, shares	1,564,549
Subsequent Event [Member] \| Extension Loan [Member]
Subsequent Event [Line Items]
Public shares redeemed per share	$ 0.05
Trust account deposit			$ 37,744	$ 37,744		$ 37,744	$ 50,000
Subsequent Event [Member] \| Common Class B [Member]
Subsequent Event [Line Items]
Common stock, shares issued		0			2,875,000
Common stock, shares outstanding		0			2,875,000
Subsequent Event [Member] \| Common Class A [Member]
Subsequent Event [Line Items]
Common stock, shares issued					2,875,000
Common stock, shares outstanding					2,875,000

Schedule of Effect of the Resta

Schedule of Effect of the Restatement (Details) - USD ($)	9 Months Ended		12 Months Ended
Schedule of Effect of the Restatement (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Jun. 30, 2024	Mar. 31, 2024	Aug. 31, 2023	Mar. 31, 2022
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Due from Sponsor	$ 1,540,984		$ 1,179,141
Total Current Assets	1,563,117		1,385,762	420,370
Total Assets	28,495,653		63,224,926	119,474,609
Note Payable - Sponsor			2,925,000
Total Current Liabilities	6,201,445		5,047,201	787,635
Total Liabilities	9,651,445		8,497,201	4,237,635
Accumulated deficit	(7,762,739)		(6,499,430)	(3,229,704)
Total Liabilities and Stockholder’s Equity	28,495,653		63,224,926	119,474,609
Capital Contribution from Sponsor	437,458		1,013,297
Proceeds from Sponsor Note	525,000	$ 3,316,485	2,925,000
Temporary equity, redemption per share							$ 10.74
Common Class A [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Class A Common Stock Subject to Possible Redemption	$ 26,606,595		$ 61,226,803	$ 118,466,326	$ 26,262,604	$ 25,922,167		$ 117,300,000
Temporary equity, redemption per share	$ 11.47		$ 11.02	$ 10.30
Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Due from Sponsor			$ 731,912
Total Current Assets			938,533
Total Assets			62,777,697
Note Payable - Sponsor
Total Current Liabilities			2,122,202
Total Liabilities			5,572,202
Accumulated deficit			(3,327,054)
Total Liabilities and Stockholder’s Equity			62,777,697
Capital Contribution from Sponsor			3,938,297
Proceeds from Sponsor Note
Temporary equity, redemption per share			$ 10.90
Previously Reported [Member] \| Common Class A [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Class A Common Stock Subject to Possible Redemption			$ 60,532,197
Revision of Prior Period, Reclassification, Adjustment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Due from Sponsor			447,229
Total Current Assets			447,229
Total Assets			447,229
Note Payable - Sponsor			2,925,000
Total Current Liabilities			2,925,000
Total Liabilities			2,925,000
Accumulated deficit			(3,172,376)
Total Liabilities and Stockholder’s Equity			447,229
Capital Contribution from Sponsor			(2,925,000)
Proceeds from Sponsor Note			$ 2,925,000
Temporary equity, redemption per share			$ 0.12
Revision of Prior Period, Reclassification, Adjustment [Member] \| Common Class A [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Class A Common Stock Subject to Possible Redemption			$ 694,606

Schedule of Deferred Taxes Asse

Schedule of Deferred Taxes Asset (Liability) (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Deferred tax asset
Start-up costs	$ 162,267	$ 98,101
Total deferred tax asset	162,267	98,101
Valuation Allowance	(162,267)	(98,101)
Deferred tax asset, net of allowance

Schedule of Income Tax Provisio

Schedule of Income Tax Provision Benefit (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Federal
Current					$ 979,344	$ 310,259
Deferred					162,267	98,101
State and Local:
Current
Deferred
Change in valuation allowance					(162,267)	(98,101)
Income tax provision	$ 43,593	$ 242,027	$ 182,072	$ 793,671	$ 979,344	$ 310,259

Schedule of Effective Income Ta

Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
U.S. federal statutory rate	(21.00%)	(21.00%)
Valuation allowance	(4.20%)	(9.80%)
Income tax provision	(25.20%)	(30.80%)

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
Income Taxes (Details Narrative) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Deferred tax assets valuation allowance.	$ 162,267	$ 98,101